BioMerieux, Banyan Biomarkers Partner to Commercialize TBI Test

Jan 19, 2017

|

NEW YORK (360Dx) – BioMérieux said today it has signed a deal to commercialize Banyan Biomarkers' tests for diagnosing traumatic brain injuries (TBI).

Under the terms of the agreement, BioMérieux will make a $7 million equity investment in Banyan in exchange for rights to commercialize Banyan's TBI tests for global use as in vitro diagnostics on BioMérieux's VIDAS immunoassay platform.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

BioMerieux, Banyan Biomarkers Partner to Commercialize TBI Test

To read the full story....

Breaking News

AACC Issues Revised Guidance on Management of Point-of-Care Testing

In Brief This Week: Quest Diagnostics, Novacyt, Natera, and More

CDC Develops Test for Simultaneous Detection of COVID-19, Flu

Randox Laboratories Invests $33.7M to Increase Coronavirus Testing Capacity

Roche Garners FDA Emergency Use Authorization for Elecsys IL-6 Test in COVID-19 Patients

Immunovia Raises $43.0M Through Stock Issuance

Featured White Papers

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

What's Popular?

Roche Garners FDA Emergency Use Authorization for Elecsys IL-6 Test in COVID-19 Patients

Beset by COVID-19 Pandemic, Europe Searches for Right Test Mix for Diagnosis, Surveillance

Randox Laboratories Invests $33.7M to Increase Coronavirus Testing Capacity

FDA Issues Emergency Use Authorizations for Gravity Diagnostics, Aspirus, CSI Coronavirus Tests

At-Home Coronavirus Tests Get Nod From FDA But Agency Proceeding With Caution

Sponsorships